GSK3β activation is a key driver of resistance to Raf inhibition in BRAF mutant melanoma cells
// Diana Crisan 1 , Susanne Schatz 2 , Heidi Hainzl 2 , Fang Zhao 3 , Annette Paschen 3 , Maria Crisan 4 , Adrian Baican 4 , Karin Scharffetter-Kochanek 1 , 2 and Abhijit Basu 2 1 Clinic of Dermatology and Allergic Diseases, University Hospital Ulm, Ulm, Germany 2 Experimental Laboratories of the Department of Dermatology and Allergic Diseases, Ulm, Germany 3 Department of Dermatology, University Hospital Essen, University Duisburg-Essen, Essen and German Cancer Consortium (DKTK), partner site Essen/Düsseldorf, Essen, Germany 4 Department of Dermatology, “Iuliu Hatieganu” University of Medicine and Pharmacy Cluj-Napoca, Romania Correspondence to: Abhijit Basu, email: [email protected] Keywords: BRAF melanoma resistance mechanisms; GSK3 β; BRAF mutation Received: October 01, 2024     Accepted: February 27, 2025     Published: April 04, 2025 Copyright: © 2025 Crisan et al. This is an open access article distributed under the terms of the Creative Commons Attribution License (CC BY 4.0), which permits unrestricted use, distribution, and reproduction in any medium, provided the original author and source are credited.
Authors
- Karin Scharffetter‐Kochanek (ORCID: https://orcid.org/0000-0002-9655-685X)
- Annette Paschen (ORCID: https://orcid.org/0000-0003-1651-1262)
- Abhijit Basu (ORCID: https://orcid.org/0000-0002-7176-250X)
- Susanne Schatz
- Heidi Hainzl
- Diana Crișan (ORCID: https://orcid.org/0000-0002-7479-5454)
- Maria Crişan
- Fang Zhao
- Adrian Baican
Institutions
- Iuliu Hațieganu University of Medicine and Pharmacy (RO)
- Düsseldorf University Hospital (DE)
- University Hospital Ulm (DE)
- Heinrich Heine University Düsseldorf (DE)
Publication Details
- Journal
- Oncotarget
- Published
- 2025-04-04
- DOI
- https://doi.org/10.18632/oncotarget.28711
- Primary Topic
- Melanoma and MAPK Pathways
- Type
- article
- Field-Weighted Citation Impact
- 0.00
Funders
- Universität Ulm